Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12988840 | 0.93 | CYP1A2 (0.44) | CYP1A2CYP2C9CYP2D6EPHX1MMP1 | |
| SCHEMBL12439392 | 0.89 | CHRNB2 (0.42) | CYP1A2CYP2C9CYP2D6EPHX1MMP1 | |
| SCHEMBL25123952 | 0.85 | CYP1A2 (0.42) | CYP1A2CYP2C9CYP2D6EPHX1MMP1 | |
| SCHEMBL2603257 | 0.84 | GPR119 (0.44) | MMP1MMP3MMP7MMP9MMP8 | |
| SCHEMBL11990216 | 0.83 | CYP2D6 (0.44) | CYP1A2CYP2C9CYP2D6EPHX1MMP1 | |
| SCHEMBL4762356 | 0.82 | GAA (0.61) | L3MBTL1THRBATMGAAALDH1A1 | |
| SCHEMBL11989587 | 0.82 | CYP1A2 (0.41) | CYP1A2CYP2C9CYP2D6EPHX1MMP1 | |
| SCHEMBL22875085 | 0.81 | GAA (0.42) | L3MBTL1THRBATMGAA | |
| SCHEMBL8299600 | 0.81 | CYP1A2 (0.42) | CYP1A2CYP2C9CYP2D6EPHX1MMP1 | |
| SCHEMBL12988217 | 0.80 | GAA (0.46) | MMP1MMP2MMP3MMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230226186-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-20 | — | — | US | disclosed |
| US-20230226186-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-20 | — | — | US | disclosed |
| US-11690915-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11690915-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| US-20110160182-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | THE UNIVERSITY OF EDINBURGH | 2010-10-21 | — | — | US | disclosed |
| US-7816348-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | AMEN INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100113439-A1 | Antifungal agents | MERCK & CO., INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-7342016-B2 | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| US-20070219176-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160182-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | CYP1A2 513/4885CYP2C9 780/4885CYP2D6 1449/4885 |
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | CYP1A2 3111/4885CYP2C9 3906/4885CYP2D6 3259/4885 |
| US-20070219176-A1 | Viral Polymerase Inhibitors | POLR2A, POLR2H, POLR2E | CYP1A2 587/4885CYP2C9 784/4885CYP2D6 465/4885 |
| US-20100137278-A1 | PYRAZINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE10A, PDE12, PDE5A | CYP1A2 513/4885CYP2C9 780/4885CYP2D6 1449/4885 |
| US-11690915-B2 | Ras inhibitors | KRAS, NRAS, HRAS | CYP1A2 4576/4885CYP2C9 3961/4885CYP2D6 3178/4885 |
| US-20100125062-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS | PDE7A, PDE9A, PDE10A | CYP1A2 979/4885CYP2C9 439/4885CYP2D6 729/4885 |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | CRBN, IKZF1, IKZF3 | CYP1A2 4596/4885CYP2C9 4731/4885CYP2D6 4691/4885 |
| US-20100113439-A1 | Antifungal agents | GMDS, GBA3, UGGT1 | CYP1A2 623/4885CYP2C9 467/4885CYP2D6 378/4885 |
| US-20230226186-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CYP1A2 4576/4885CYP2C9 3961/4885CYP2D6 3178/4885 |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, PRKCSH | CYP1A2 861/4885CYP2C9 1794/4885CYP2D6 534/4885 |
| US-20100267696-A1 | Amido-Thiophene Compounds and Their Use as 11-Beta-HSD1 Inhibitors | HSD11B1, HSD11B2, HSD17B1 | CYP1A2 145/4885CYP2C9 319/4885CYP2D6 437/4885 |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE4A, PDE7A, PDE4D | CYP1A2 1374/4885CYP2C9 288/4885CYP2D6 510/4885 |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CYP1A2 3256/4885CYP2C9 4435/4885CYP2D6 3436/4885 |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI2, PADI6 | CYP1A2 380/4885CYP2C9 272/4885CYP2D6 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.